Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of ASP015K Tablets in Healthy Males
NCT02531191Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peficitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve from the time of dosing to the time of the last sampling up to 72 hours and Maximum concentration up to 72 hours. Started Jun 2015; status: completed.
02
Drugs
peficitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02531191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531191.